Primary prevention of cardiovascular diseases

Scandinavian Journal of Primary Health Care

Volumn 21, Issue 2, 2003, Pages 68-74

  Sigurdsson, Emil L ^a   Thorgeirsson, Gudmundur ^b  

^a Health Center of Hafnarfjordur   (Iceland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HYPOCHOLESTEROLEMIC AGENT; MEDROXYPROGESTERONE ACETATE; STATINE;

BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC DIET; DRUG EFFICACY; DRUG SAFETY; HAZARD ASSESSMENT; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; OBESITY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; SMOKING CESSATION;

CARDIOVASCULAR DISEASES; HUMANS; PRIMARY PREVENTION; RISK FACTORS;

EID: 0038464636     PISSN: 02813432     EISSN: None     Source Type: Journal    
DOI: 10.1080/02813430310000717     Document Type: Review

References (63)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-48.
2. American Heart Association 2002. Heart and stroke statistical update. Dallas, Texas: American Heart Association 2001;4-5.
3. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988;41:155-78.
4. Sigfusson N, Sigvaldason H, Steingrimsdottir L, Gudmundsdottir II, Stefansdottir I, Thorsteinsson T, et al. Decline in ischaemic heart disease in Iceland and change in risk factor levels. BMJ 1991;302:1371-5.
5. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994;309:23-7.
6. Ounpuu S, Yusuf S. Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition. Eur Heart J 2003;24:127-9.
7. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-503.
8. Pearson TAMP, Blair SNP, Daniels SRMP, Eckel RHM, Fair JMRP. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular disease. Circulation 2002;106:388-91.
9. Grundy SMMPC, Balady GJM, Criqui MHM, Fletcher GM, Greenland PM. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998;97:1876-87.
10. Third Report of the National Cholesterol Education Program. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, and Blood Institute (NIH Publication No. 02-5215. September 2002). Circulation 2002;106:3143-420.
11. Bonow ROM. Primary prevention of cardiovascular disease: a call to action. Circulation 2002;106:3140-1.
12. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.
13. Pearson TA, Bazzarre TL, Daniels SR, Fair J, Fortmann SP, Franklin BA, et al. American heart association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association expert panel on population and prevention. Circulation 2003;107:645-51.
14. Jousilahti PMM, Tuomilehto JMPM, Vartiainen EMP, Pekkanen JMP, Puska P. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996;93:1372-9.
15. Fortmann SP, Varady AN. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: the Stanford five-city. Am J Epidemiol 2000;152:316-23.
16. Lingfors H, Lindström K, Persson L-G, Bengtsson C, Lissner L. Evaluation of "Live for Life", a health promotion programme in the county of Skaraborg, Sweden. J Epidemiol Community Health 2001;55:277-82.
17. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998;9:S5-S15.
18. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72.
19. Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G. Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J Intern Med 1997;242:199-211.
20. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988;62:1109-12.
21. Kawachi IM, Colditz GAM, Speizer FEM, Manson JEM, Stampfer MJM, Willett WC. A prospective study of passive smoking and coronary heart disease. Circulation 1997;95:2374-9.
22. Schwartz JL. Review and evaluation of smoking cessation methods: The United States and Canada, 1978-1985. DHHS publication no. (NIH)87-2940, Bethesda, MD, US Government Printing Office, 1987.
23. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomized trial in healthy men. Lancet 1981;2:1303-10.
24. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
25. Moser M, Hebert P, Hennekens CH. An overview of the meta-analyses of the hypertension treatment trials. Arch Intern Med 1991;151:1277-9.
26. Keys A, Arvanis C, Blackburn H. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980.
27. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rate. Circulation 1994;90:583-612.
28. Krauss RM, Deckelbaum RJ, Ernst N, Fisher E, Howard BV, Knopp RH, et al. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. Circulation 1996;94:1795-800.
29. National Heart, Lung, and Blood Institute National Institutes of Health. National Cholesterol Education Program. NIH Publication, no. 02-5215 September 2002.
30. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment. JAMA 1993;269:3015-23.
31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. N Engl J Med 1995;333:1301-7.
32. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is... or is it? Lancet 1997;350(Suppl 1):14-9.
33. Haffner SM, Agostino Jr RD, Saad MF, O'Leary DH, Savage PJ, Rewers M, et al. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease. Am J Cardiol 2000;85:1395-400.
34. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1569-82.
35. Adler AI, Stratton IM, Neil H, Andrew W, Yudkin JS, Matthews DR, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
36. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: ukpds 38. BMJ 2000;317:703-12.
37. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26:S80-2.
38. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26:S33-50.
39. Gaede P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.
40. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
41. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.
42. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al. Weight, weight change, and coronary heart disease in women. Risk within the "normal" weight range. JAMA 1995;273:461-5.
43. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117-27.
44. Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24-32.
45. Vartiainen E, Sarti C, Tuomilehto J, Kuulasmaa K. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland. BMJ 1995;310:901-4.
46. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
47. US Department of Health and Human Services. Physical Activity and Health. 1999;102-12.
48. Helmrich SP, Ragland DR, Leung RW, Paffenbarger Jr RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147-52.
49. Agnarsson U, Thorgeirsson G, Sigvaldason H, Sigfusson N. Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: the Reykjavik Study. Ann Intern Med 1999;130:987-90.
50. Iso H, Hennekens CH, Stampfer MJ, Meir J, Rexrode KM, Colditz GA, et al. Prospective study of aspirin use and risk of stroke in women. Stroke 1999;30:1764-71.
51. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
52. Hebert PRP, Hennekens CHM. An overview of the four randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med 2000;160:3123-7.
53. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:983-6.
54. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised control trial. BMJ 2000;321:13-7.
55. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study. N Engl J Med 1989;321:129-35.
56. Boissel JP. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA 1998;280:1949-50.
57. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
58. Smith GD, Egger M. Who benefits from medical interventions? BMJ 1994;308:72-4.
59. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
60. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
61. Berenson GS, Srinivasan SR, Bao W, Newman 3rd WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults (The Bogalusa Heart Study). N Engl J Med 1998;338:1650-6.
62. Berenson GS, Wattigney WA, Tracy RE, Newman 3rd WP, Srinivasan SR, Webber LS, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol 1992;70:851-8.
63. Sigurdsson EL, Jonsson JS, Thorgeirsson G. Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland. Scand J Prim Health Care 2002;20:10-5.